#USA #G-Rex Grant #ScaleReady #Saint Paul #Gates Institute

ScaleReady Announces G-Rex® Grant Award to Gates Institute

In a significant development for cell and gene therapy, ScaleReady has partnered with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady to announce a $300,000 G-Rex® Grant awarded to the Translational Sciences Laboratory at the Gates Institute. Located at the University of Colorado Anschutz Medical Campus, this institute stands out as a leading contract development and manufacturing organization (CDMO) committed to bridging the gap between academic research and clinical application.

Supporting Innovative Therapies

The funding will focus on launching a flexible, modular G-Rex centered CAR T-cell manufacturing platform, aiming to streamline production methods for cell and gene therapy programs. Dr. Veena Krishnamoorthy, the Director of Translational Sciences at the Gates Institute, expressed gratitude for this opportunity, emphasizing how it will back the development of adaptive manufacturing strategies. Such initiatives are crucial in optimizing resource use without compromising the quality of cellular products.

“We appreciate the support from Wilson Wolf and Bio-Techne in advancing our work and the broader CGT field,” Dr. Krishnamoorthy stated.

John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, echoed this sentiment, highlighting the importance of supporting innovative research that contributes to effective therapies for challenging diseases.

Further Enhancements in Research

As part of the G-Rex Grant’s fabric, the Gates Institute will implement a structured Design of Experiments (DoE) to refine critical steps in CAR-T cell manufacturing. This systematic approach will involve assessing vital variables influencing the manufacturing process, thus enhancing the potential for varied production paths within well-defined parameters for novel cell therapies.

The Gates Institute will also gain exclusive early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation. This collaboration is expected to facilitate high-throughput manufacturing at lower costs, fostering advancements in the clinical efficacy of therapies targeting severe cancers and rare diseases.

A Broader Impact on Cell Therapy Development

ScaleReady’s G-Rex Grant initiative has invested more than $40 million in its various programs, aiming to better the landscape of cell and gene-modified cell therapies. Each individual grant can reach up to $300,000, and recipients of the G-Rex Grants benefit from comprehensive support from ScaleReady's esteemed group of partners who provide valuable insights into cGMP manufacturing and regulatory affairs.

Moreover, ScaleReady recently announced another proactive program designed to enhance the efficiency of CGT manufacturing. In collaboration with Hanson Wade, the LEAN Cell Gene™ event series will equip all stakeholders in the CGT field with essential strategies to streamline operations, improve drug quality, and foster a more economical approach to therapy development.

About the Collaborators

The Gates Institute is esteemed for its rapid translational research capabilities, taking significant strides in regenerative medicine. By fostering a collaborative environment for researchers and clinicians, it accelerates breakthroughs across various disease states.

ScaleReady, recognized for its innovative G-Rex manufacturing platform, has empowered numerous organizations by significantly speeding up development timelines and reducing costs associated with CGT. The increasing number of clinical trials employing this platform, now surpassing 50%, underscored its crucial role in the evolution of cell therapies.

For more information about the G-Rex® Grant Program, interested parties can contact ScaleReady directly. Through these collective efforts, the potential for revolutionary therapies to combat life-threatening conditions remains within reach, promising renewed hope to patients worldwide.